Protecting Americans from Unsafe Drugs Act of 2026
- Sponsor
- Rep. Dexter, Maxine [D-OR-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Mar 18, 2026
Bottom line
This bill significantly broadens the FDA's power to mandate recalls and halt distribution for any drug deemed unsafe, moving beyond its current limitation to only controlled substances, thereby enhancing comprehensive drug safety oversight.
What it actually does
This bill expands the Food and Drug Administration's (FDA) authority to order the cessation of distribution and recall of drugs. Currently, this authority under Section 569D of the Federal Food, Drug, and Cosmetic Act (FDCA) is limited to controlled substances. This bill amends the FDCA to apply this mandatory recall authority to all drugs, and also prohibits the import or export of any drug subject to such an order. It further clarifies that the Director of the Center for Biologics Evaluation and Research (CBER) can also issue such orders.
Proponents argue
Proponents argue that this bill closes a critical loophole in drug safety regulation, allowing the FDA to act swiftly and decisively to protect public health from any unsafe drug, not just controlled substances. They would assert that it provides the agency with necessary tools to prevent widespread harm and ensures a consistent standard of safety across all pharmaceutical products, ultimately safeguarding consumers more effectively.
Opponents contend
Opponents might argue that expanding the FDA's mandatory recall authority to all drugs could lead to overreach, stifle innovation, or impose undue burdens on pharmaceutical manufacturers, potentially causing drug shortages or delays in getting new treatments to market. They may also raise concerns about the potential for arbitrary application of this power without sufficient checks and balances, impacting industry stability.
The bill text is very short and straightforward, making it easy for any reader to understand its direct legislative changes and the core policy shift it proposes.
Section 2(a) and 2(b) of H.R. 7980, amending Sections 569D and 801(a) of the Federal Food, Drug, and Cosmetic Act
Expanding FDA Mandatory Recall and Nondistribution Authority to All Drugs
This provision amends existing law by replacing references to "controlled substance" with "drug" in the FDA's authority to order a halt to distribution and recall. Previously, the FDA could only issue such mandatory orders for controlled substances. With this change, the FDA gains the power to compel the recall and halt the distribution of any drug that poses a threat to public health. It also ensures that drugs subject to such an order cannot be imported or exported, and clarifies that the Director of the Center for Biologics Evaluation and Research (CBER) can also issue these orders.
Supporters argue
Supporters argue that this expansion is a crucial step to safeguard public health, allowing the FDA to respond comprehensively to safety concerns across the entire drug supply, not just a subset. They emphasize that voluntary recalls are not always sufficient and mandatory authority ensures prompt action when necessary to protect consumers.
Critics contend
Critics might contend that this broad expansion of power could lead to arbitrary decisions, increase regulatory burdens on manufacturers, and potentially disincentivize drug development due to heightened risk of mandatory intervention. They may argue that existing voluntary recall mechanisms are largely effective and that mandatory recalls should be reserved for specific, high-risk categories.
Tradeoffs
The bill balances the desire for enhanced public safety through stronger regulatory enforcement against potential concerns about regulatory overreach, industry burden, and the impact on drug innovation and availability.